Clover Health Investments, CORP /DE 8-K filings

Clover Health disclosed a cybersecurity incident on July 4, 2026, involving unauthorized access to employee accounts, with an ongoing investigation into data impact.

Clover Health Investments, Corp. successfully concluded its 2026 Annual Meeting with shareholders electing directors and ratifying its accounting firm.

Clover Health Investments, Corp. announced a favorable court ruling and subsequent recalculation of its 2026 Medicare Star Rating to 4.5 stars, impacting over 97% of its members.

Clover Health released supplemental Q&A addressing Q1 2026 performance, business outlook, and long-term strategy, emphasizing Clover Assistant's impact on medical costs and margin expansion.

Clover Health Investments, Corp. announced the departure of CFO Peter Kuipers and the appointment of Clay Thornton as Interim CFO, while reiterating its full fiscal year 2026 financial guidance.

Clover Health outlines its strategy for achieving full-year GAAP Net Income profitability in 2026, emphasizing cohort maturation, Clover Assistant engagement, and operating leverage.

Clover Health Investments, Corp. published responses to frequently asked supplemental questions following its fourth quarter 2025 earnings announcement.

Clover Health reported strong full year 2025 financial results, achieving Adjusted EBITDA profitability and significant membership growth, while projecting its first-ever full year of GAAP Net Income profitability in 2026.

Clover Health announced a 53% year-over-year increase in Medicare Advantage membership to 153,000, projecting its first full year GAAP Net Income profitability in 2026.

Clover Health's subsidiary, Counterpart Health, Inc., announced the release of information regarding its Counterpart Assistant technology's performance outcomes and third-party clinician adoption.

Clover Health released a supplemental Q&A addressing third-quarter 2025 medical cost pressures, its 2026 outlook, Star Ratings, and the growth of its Clover Assistant and Counterpart Health platforms.

Clover Health Investments, Corp. announced its third quarter 2025 financial results, reporting significant membership and revenue growth but revising down its full-year 2025 profitability guidance.

Chelsea Clinton, the longest-serving member of Clover Health's Board of Directors, has concluded her service effective October 31, 2025, after over eight years.

Clover Health announced its 2026 Medicare Advantage Star Ratings, receiving 3.5 Stars for PPO plans and 4.0 Stars for HMO plans, while reiterating confidence in future profitability and growth.

Clover Health released shareholder Q&A responses, emphasizing its unique PPO model success and advanced AI integration in healthcare.

Clover Health announced robust second quarter 2025 results, showcasing significant membership and revenue growth while updating its full-year guidance.

Clover Health Investments, Corp. announced the successful passage of all three proposals at its 2025 Annual Meeting of Stockholders, including the re-election of two Class I directors, the non-binding approval of executive compensation, and the ratification of Ernst & Young LLP as its independent auditor.

Clover Health outlines its strategy for sustained profitability and growth, leveraging improved Star Ratings and the expansion of its Counterpart Health platform.

Clover Health announces positive Q1 2025 results with increased membership, revenue, and profitability, leading to improved full-year guidance.

Lee A. Shapiro will not stand for re-election to Clover Health's Board of Directors, with Thomas L. Tran stepping into the roles of Chairman of the Audit Committee and the Nominating and Corporate Governance Committee.

Clover Health's full year 2024 results show significant improvement in profitability and revenue growth, leading to a positive outlook for 2025.

Clover Health reports a significant 27% year-over-year increase in Medicare Advantage membership, exceeding 100,000 members, driven by strong plan benefits and a 4-Star rating.

Clover Health announced strong third-quarter 2024 financial results, including improved profitability and increased full-year Adjusted EBITDA guidance.

Clover Health has agreed to pay $250,000 to settle a shareholder lawsuit regarding a bylaw amendment, avoiding further litigation costs.

Clover Health's PPO Medicare Advantage plans have received a 4-Star rating from CMS for 2025, leading to an expected 5% increase in benchmark rates for payment year 2026.

The Securities and Exchange Commission has concluded its investigation into Clover Health, with the staff deciding not to recommend any enforcement action.

Clover Health has appointed Thomas L. Tran, a seasoned healthcare financial executive, to its Board of Directors and Audit Committee, increasing the board size to nine members.

Clover Health reports its first profitable quarter as a public company, driven by strong revenue growth and improved cost management, leading to an increased full-year outlook.

A U.S. District Court has approved the settlement of multiple shareholder derivative lawsuits against Clover Health, resolving claims against the company and its former officers and directors.

Clover Health has received formal notice from Nasdaq confirming it has regained compliance with the minimum bid price requirement.